CD20 Stock Overview
Nelly Group AB (publ) operates as a fashion company in Sweden, the rest of the Nordics, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Nelly Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.26 |
| 52 Week High | kr1.64 |
| 52 Week Low | kr0.27 |
| Beta | 1.44 |
| 1 Month Change | -14.42% |
| 3 Month Change | -15.57% |
| 1 Year Change | 185.91% |
| 3 Year Change | -65.34% |
| 5 Year Change | -88.93% |
| Change since IPO | -96.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| CD20 | DE Specialty Retail | DE Market | |
|---|---|---|---|
| 7D | -4.1% | -2.4% | 1.7% |
| 1Y | 185.9% | -20.3% | 2.3% |
Return vs Industry: CD20 exceeded the German Specialty Retail industry which returned -18.3% over the past year.
Return vs Market: CD20 exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| CD20 volatility | |
|---|---|
| CD20 Average Weekly Movement | 6.7% |
| Specialty Retail Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CD20's share price has been volatile over the past 3 months.
Volatility Over Time: CD20's weekly volatility has decreased from 16% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1936 | 158 | Helena Karlinder-Ostlundh | www.nellygroup.com |
Nelly Group AB (publ) operates as a fashion company in Sweden, the rest of the Nordics, and internationally. The company offers clothing, accessories, beauty products, and sportswear, as well as lingerie, and swimwear for women under the Nelly brand. It sells and markets its products online through Nelly.com and NLYman.com.
Nelly Group AB (publ) Fundamentals Summary
| CD20 fundamental statistics | |
|---|---|
| Market cap | €38.92m |
| Earnings (TTM) | -€128.84k |
| Revenue (TTM) | €91.11m |
0.4x
P/S Ratio-302.1x
P/E RatioIs CD20 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CD20 income statement (TTM) | |
|---|---|
| Revenue | kr1.06b |
| Cost of Revenue | kr552.90m |
| Gross Profit | kr507.90m |
| Other Expenses | kr509.40m |
| Earnings | -kr1.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | -0.05 |
| Gross Margin | 47.88% |
| Net Profit Margin | -0.14% |
| Debt/Equity Ratio | 0% |
How did CD20 perform over the long term?
See historical performance and comparison